CLEARBRIDGE HEALTH LIMITED

SGX: 1H3 (Clearbridge)

最近更新时间: 08 Jun, 1:23AM

0.003

0.00 (0.00%)

前收盘价格 0.003
收盘价格 0.003
成交量 1,801,100
平均成交量 (3个月) 2,740,291
市值 6,506,159
预期市盈率 (P/E Forward) 0.160
价格/销量 (P/S) 0.140
股市价格/股市净资产 (P/B) 0.470
52周波幅
0.002 (-33%) — 0.014 (366%)
利润日期 28 Feb 2025
营业毛利率 -36.43%
营业利益率 (TTM) -24.93%
稀释每股收益 (EPS TTM) -0.010
季度收入增长率 (YOY) 3.90%
总债务/股东权益 (D/E MRQ) 56.44%
流动比率 (MRQ) 0.870
营业现金流 (OCF TTM) -1.98 M
资产报酬率 (ROA TTM) -10.99%
股东权益报酬率 (ROE TTM) -34.63%

市场趋势

短期 中期
行业 Diagnostics & Research (SG) 混合的 混合的
Diagnostics & Research (全球的) 看跌 看跌
股票 Clearbridge - -

AIStockmoo 评分

-1.1
分析师共识 0.0
内部交易活动 NA
价格波动 -2.0
技术平均移动指标 -2.5
技术振荡指标 0.0
平均 -1.13

相关股票

股票 市值 DY P/E(TTM) P/B
CLEARBRIDGE 7 M - - 0.470
CORDLIFE 69 M - - 0.620
HC SURGICAL 45 M 5.36% 14.00 2.62
BIOLIDICS 37 M - - 21.48
ASIAMEDIC 14 M - - 0.950

Clearbridge Health Ltd provides health care services. It is an integrated healthcare group with end-to-end diagnostic abilities, deploying non-invasive tests to identify and manage illness. The segments are Strategic investments; Healthcare systems; Medical clinics; Corporate segment and Investment. It derives key revenue from the Healthcare systems and Medical clinics. The Healthcare systems segment involves, the provision of diagnostic services manufacturing of and research and development on diagnostic-related products, and provision of renal care services by partnering with medical device equipment manufacturers and hospitals. The Medical clinics segment involves, the provision of general medical and clinical services. The group has a business presence all over the world.

部门 Healthcare
行业 Diagnostics & Research
投资方式 Small Value
内部持股比例 46.41%

所有权

姓名 日期 持有股份
Chen (Johnson) 10 Dec 2024 154,110,200 (8.29%)
Yee (Pinh Jeremy) 10 Dec 2024 83,055,831 (4.47%)
Bonvests Holdings Ltd 19 Mar 2024 41,330,500 (2.22%)
Amereus Group Pte. Ltd. 19 Mar 2024 39,771,600 (2.14%)
Chen (Chung Ni Johnny) 10 Dec 2024 31,059,800 (1.67%)

该时间范围内无数据。

该时间范围内无数据。

日期 类型 细节
19 Jun 2025 公告 Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)::Disclosure of Change in interest of Substantial Shareholders - Wong Kong Leong
16 Jun 2025 公告 Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)::Cessation of Substantial Shareholder - Ong Choon Yi
16 Jun 2025 公告 Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)::Becoming a Substantial Shareholder - Wong Kong Leong
12 Jun 2025 公告 Change - Change of Catalist Sponsor::Change of Continuing Sponsor
06 Jun 2025 公告 General Announcement::ENTRY INTO STRATEGIC ALLIANCE AGREEMENT
29 May 2025 公告 General Announcement::Minutes of the Annual General Meeting held on 30 April 2025
06 May 2025 公告 Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)::Disclosure of Change in interest of Substantial Shareholders - Ong Choon Yi
06 May 2025 公告 Disclosure of Interest/ Changes in Interest of Substantial Shareholder(s)/ Unitholder(s)::Disclosure of Change in interest of Substantial Shareholders-Coop International & Bonvests Holdings
06 May 2025 公告 Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Disclosure of Change in Director's Interest - Yee Pinh Jeremy
06 May 2025 公告 Disclosure of Interest/ Changes in Interest of Director/ Chief Executive Officer::Disclosure of Change in Director's Interest - Chen Johnson
02 May 2025 公告 General Announcement::PROPOSED ISSUE OF CONVERTIBLE BONDS - CONVERSION OF CONVERTIBLE BONDS
30 Apr 2025 公告 General Announcement::Cessation of Quarterly Reporting of Financial Statements
30 Apr 2025 公告 General Announcement::PROPOSED ISSUE OF CONVERTIBLE BONDS - RECEIPT OF LISTING AND QUOTATION NOTICE
30 Apr 2025 公告 REPL::Annual General Meeting::Voluntary
28 Apr 2025 公告 General Announcement::ENTRY INTO BINDING TERM SHEET FOR THE PROPOSED ACQUISITION OF ELPIS BIOPHARMACEUTICALS PTE. LTD.
14 Apr 2025 公告 Annual Reports and Related Documents::
14 Apr 2025 公告 Annual General Meeting::Voluntary
10 Apr 2025 公告 General Announcement::Minutes of the Extraordinary General Meeting held on 12 March 2025
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票